![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BiologicTx Desensitization Data Shows Reduced Time to Transplant, Lower Risk of AMR Post-Transplant
BiologicTx Desensitization Data Shows Reduced Time to Transplant, Lower Risk of AMR Post-Transplant
BiologicTx has released positive three-year clinical outcomes data for patients treated with desensitization therapy resulting in a successful transplant.
In all 421 patients, the primary therapeutic modality was IVIg 2g/kg per month infused through BiologicTx therapeutic services in an outpatient setting.
According to clinical results, of 361 patients, 111 have reached transplant, achieving an effective transplant rate of 30.7 percent. — Cynthia Jessup
Upcoming Events
-
21Oct